NCT06877533

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: iTeos Belgium SA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). The study includes EOS006215 monotherapy and combination therapy with other anticancer agents in participants with advanced solid tumors.

Detailed description

The study will be conducted in 2 parts: * Part 1 - Dose Escalation Phase I dose escalation cohorts for EOS006215 as monotherapy and in combination with anticancer treatments in participants with specific tumor types. * Part 2 - Dose Expansion Phase Ib dose expansion cohort(s) may be included to further evaluate the safety, tolerability, efficacy, PK and PD of EOS006215 as monotherapy or in combination with anticancer treatments in participants with specific tumor types.

Conditions

• Selected Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	EOS006215	Multiple doses of EOS006215
DRUG	Anticancer agent	Multiple doses of EOS006215 in combination with other anticancer agents

Timeline

• Start date: 2025-04-07
• Primary completion: 2025-07-10
• Completion: 2025-07-10
• First posted: 2025-03-14
• Last updated: 2025-08-12

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study